LILLY'S JAYPIRCA (PIRTOBRUTINIB), THE FIRST-AND-ONLY APPROVED NON-COVALENT BTK INHIBITOR, RECEIVES EXPANDED INDICATION FROM U.S. FDA FOR CERTAIN PATIENTS WITH PREVIOUSLY UNTREATED CLL/SLL

Reuters · 3d ago

Please log in to view news